Xuanzhu Biopharmaceutical Co Ltd, a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group, has secured over 610.5 million yuan ($96 million) in its Series B round of financing led by Sunshine Insurance Group.
The latest round brings the company’s market valuation to 7 billion yuan ($1.1 billion).
Bank of China’s BOCGI, Efung Capital, China Zhongji Investment, TJ Capital, SDIC Taikang Trust and Qianhai FOF joined the round.
WinX Capital served as the financial advisor for the deal.
Xuanzhu will use the proceeds for its pipeline candidates and technology innovation, it said.
Xuanzhu develops drugs targeting therapy areas associated with cancers, metabolic disorders and infectious diseases.
CHINA DEAL MONITOR
DealStreetAsia has also put together a table listing out all prominent venture capital transactions in the Greater China region on December 27, 2021 – January 04, 2022.
